

19 Nov 2019 | News

QUOTED. 19 November 2019. Benjamin Bertrand.

by

Cardiawave's non-invasive ultrasound therapy is feasible and safe in patients with severe symptomatic aortic stenosis, according to early trial results presented at the annual American Heart Association meeting. See what Cardiawave's CEO, Benjamin Bertrand, said about it here.

"We're working early on to make sure clinical trial, endpoints, sample size and follow-up data requirements [are discussed with the reimbursement bodies] to help with reimbursement. As you know, reimbursement in each EU country is different, so we're having those conversations with the relevant organizations early." – Benjamin Bertrand, CEO, Cardiawave

Find out more: [AHA 2019: Cardiawave Sees Positive Early Results For Non-Invasive 'Alternative' To TAVR](#)

[Click here](#) for a free trial of *Medtech Insight*